Citigroup’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Citigroup’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Hold	0	–	–	–	6402
2021 Q2	–	Sell	-56	Closed	-$6.19K	–	6477
2021 Q1	$8K	Sell	56 -106	-65%	-$19.2K	﹤0.01%	5779
2020 Q4	$23K	Buy	162 +122	+305%	+$19.8K	﹤0.01%	6572
2020 Q3	$6K	Sell	40 -76	-66%	-$12.4K	﹤0.01%	6948
2020 Q2	$20K	Buy	116 +67	+137%	+$11.2K	﹤0.01%	6634
2020 Q1	$7K	Buy	+49	New	+$6.48K	﹤0.01%	7194
2016 Q1	–	Hold	0	–	-$1K	–	7840
2015 Q4	–	Sell	-4	Closed	-$6.14K	–	7435
2015 Q3	$4K	Hold	4	–	–	﹤0.01%	6850
2015 Q2	$4K	Sell	4 -3	-43%	-$3.23K	﹤0.01%	6909
2015 Q1	$7K	Sell	7 -2	-22%	-$6.6K	﹤0.01%	6619
2014 Q4	$31K	Buy	9 +7	+350%	+$21.5K	﹤0.01%	5992
2014 Q3	$5K	Buy	+2	New	+$6.62K	﹤0.01%	6578
2014 Q2	–	Sell	-3	Closed	-$11.3K	–	6789
2014 Q1	$15K	Buy	+3	New	+$15.8K	﹤0.01%	6178

Other funds holding NBSE

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citigroup's NBSE Position: Q3 2021 in Review

Citigroup held its NeuBase Therapeutics, Inc. Common Stock (NBSE) position steady in Q3 2021 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #6402.

Citigroup first reported a position in NBSE in Q1 2014 and has held it in 11 quarters since. The position peaked at $31K in Q4 2014. 47 funds tracked by Wall St. Rank hold NBSE as of Q3 2021.

Citigroup held 0 shares of NeuBase Therapeutics, Inc. Common Stock worth $0 as of Q3 2021.
Citigroup left its NeuBase Therapeutics, Inc. Common Stock share count unchanged in Q3 2021.
NeuBase Therapeutics, Inc. Common Stock made up ﹤0.01% of Citigroup's portfolio in Q3 2021, its #6402 holding.
Citigroup first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2014 and has held it in 11 quarters since.
Citigroup's NeuBase Therapeutics, Inc. Common Stock position peaked at $31K in Q4 2014.
47 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Citigroup's 13F filing for Q3 2021, filed 10 Nov 2021.